

# CONTENTS

<i>Preface</i>	xvii
<i>Acknowledgements</i>	xxi
<b>1. Health Care Spending Growth</b>	<b>1</b>
Michael E. Chernew, Joseph P. Newhouse	
1. Introduction	2
1.1. Spending Growth in the US	2
1.2. Spending Growth in Other Countries	4
2. Spending Growth vs. Spending Level	5
3. Technology and Spending Growth	7
4. Models of Spending Growth	10
4.1. Models with Exogenous Technology	10
4.2. Models of Endogenous Technology	12
5. Empirical Evidence	17
5.1. Causes of Spending Growth	17
5.2. Spending Growth by Insurance Type	26
5.3. Spending Growth by Disease/Health Status	34
6. Value of Spending Growth	36
7. Conclusion	37
References	38
<b>2. Causes and Consequences of Regional Variations in Health Care</b>	<b>45</b>
Jonathan Skinner	
1. Introduction	46
2. An Economic Model of Regional Variations in Health Care	48
2.1. The Demand Side	49
2.2. The Supply Side	50
2.3. A typology of health care services	54
3. Empirical Evidence on Geographic Variations in Expenditures and Utilization	57
3.1. Units of Measurement and Spatial Correlations	57
3.2. Health Care Expenditures	59
3.3. Effective Care (Category I)	66
3.4. Preference-sensitive Treatments with Heterogeneous Benefits (Category II)	67
3.5. Supply-sensitive (Category III) Treatments with Unknown or Marginal Benefits	71

4. Estimating the Consequences of Regional Variation: Geography As An Instrument	75
5. Inefficiency and the Policy Implications of Regional Variations	81
6. Regional Variations in Health Outcomes	83
7. Discussion and Conclusion	85
References	86
<b>3. The Economics of Risky Health Behaviors</b>	<b>95</b>
John Cawley, Christopher J. Ruhm	
1. Introduction	97
1.1. The Importance of Health Behaviors	97
1.2. Trends in Health Behaviors	100
1.3. Differences in Health Behaviors across Population Subgroups	103
1.4. Health Economics Research on Health Behaviors	108
2. The Traditional Economic Approach to Studying Health Behaviors	110
2.1. Model of Health Capital	110
2.2. Education and Health Behaviors	111
2.3. Habit and Addiction	112
2.4. Price Elasticities of Health Behaviors	121
2.5. Income and Health Behaviors	126
2.6. The Role of Advertising	128
2.7. Time Preference and Health Behaviors	130
3. Alternative Approaches to Studying Health Behaviors	133
3.1. Peer Effects	133
3.2. Information Constraints	137
3.3. Time-inconsistent Preferences and Hyperbolic Discounting	139
3.4. Cognitive Limitations and Bounded Rationality	141
3.5. Non-traditional Models	144
3.6. Short-term Effects	151
4. Economic Consequences of Health Behaviors	155
4.1. Reasons to (and not to) Conduct Cost of Behavior Studies	155
4.2. Challenges to Identifying the Consequences of Health Behaviors	156
4.3. Impacts on Medical Care Costs	157
4.4. Impacts on Education	158
4.5. Impacts on Employment	160
4.6. Impacts on Income, Earnings, and Wages	161
4.7. Impacts on Crime	162
5. Strategies for Modifying Health Behaviors	163
5.1. Taxes and Subsidies	163
5.2. Cash Incentives for Healthy Behaviors	170
5.3. Restrictions on Purchase or Use	172

5.4. Providing Information	175
5.5. Advertising Restrictions	177
5.6. Defaults and Choice Architecture	178
6. Future Directions	178
6.1. Future Research using Traditional Economic Models	179
6.2. Future Research using Non-traditional Models	181
References	182

#### **4. Improving Health in Developing Countries: Evidence from Randomized Evaluations** **201**

**Michael Kremer, Rachel Glennerster**

1. Introduction	202
2. Conceptual Framework for Household Decision Making	206
2.1. Health as Human Capital Investment	206
2.2. Cost-effectiveness Analysis	210
3. Externalities and Public Goods	212
3.1. Non-excludable Public Goods	212
3.2. Excludable Public Goods	217
4. The Impact of Price and Convenience on Prevention Behavior Against Infectious Disease	220
4.1. Evidence on Pricing and Demand for Preventive and Non-acute Care	225
4.2. Distance, Convenience, and Take-up	229
4.3. Pricing and Targeting	231
5. Incentives	231
5.1. Conditional Cash Transfer Programs	231
5.2. Small Incentive Programs	236
6. Consumer Behavior, Acute Treatment, and Insurance	237
6.1. Consumer Behavior and Acute Treatment	238
6.2. Insurance	242
7. Liquidity Constraints and Consumer Behavior	244
8. Behavioral Models and Health	247
8.1. Present Bias	248
8.2. Deliberation Costs and Limited Attention	252
8.3. Pricing and Use: Testing the Sunk Cost Fallacy Hypothesis	253
8.4. Endowment Effects	255
8.5. Learning vs. Price Anchoring: Long-term Implications of Free Delivery	256
9. Information and Health Education	256
9.1. General Education	257
9.2. Complementarities between Education and Subsidies	263
9.3. Information on Individual and Local Risk Factors	264

10. Social Influences on Health Behavior	269
11. Health Care Supply in the Developing World: Background	273
11.1. Public Health Care	273
11.2. Private Health Care	276
12. Health Care Delivery and System Reform	277
12.1. Paying for Provider Presence in India and Rwanda	278
12.2. Contracting for Health in Post-conflict Cambodia	281
12.3. Paying for Results at the Community Level	283
12.4. Community Mobilization, Accountability, and Reform	284
13. Interactions between Health and Broader Socio-Economic Variables	286
13.1. Impact of Economic and Social Factors on Health	286
13.2. The Impact of Health on Other Economic Variables	294
14. Conclusion	298
14.1. Policy Implications	299
14.2. Directions for Future Research	301
References	304

## **5. Demand for Health Insurance 317**

**Thomas G. McGuire**

1. Introduction and Overview: Health Systems With Choice of Health Insurance	319
1.1. United States	321
1.2. High-income Countries	331
1.3. Middle-income Countries	336
2. Optimal Demand-Side Cost Sharing	338
2.1. Optimal Health Insurance Basics with no Moral Hazard	340
2.2. Overview of Topics in Optimal Health Insurance	340
2.3. Optimal Health Insurance: First-best Benchmark	342
2.4. Demand Response (Moral Hazard) and a Second-best Coverage	344
2.5. Multiple Services, Cross-price Elasticity of Demand, Offsets	351
2.6. Health Insurance to Correct Consumer Mistakes in Demand for Health Care	356
3. Supply-Side Policies and Demand-Side Coverage	360
3.1. Supply-side Policies	361
3.2. Demand-side Cost Sharing and Selective Contracting	366
4. Structuring Choice of Health Insurance	373
4.1. "Price" and "Quantity Demanded" of Health Insurance	373
4.2. Arguments For and Against Choice in Health Insurance	375
4.3. Premium Setting and Fairness	385
5. Final Comments	386
References	387

<b>6. Who Ordered That? The Economics of Treatment Choices in Medical Care</b>	<b>397</b>
<i>Amitabh Chandra, David Cutler, Zirui Song</i>	
1. Introduction	398
1.1. Overview of Variations in Medical Care	400
1.2. Gray Area of Medicine	402
1.3. Demand (Patients) and Supply (Doctors)	403
2. Heterogeneity In Demand	406
2.1. Price and Income Effects: Theory	406
2.2. Empirical Evidence on Price and Income Effects	407
2.3. Preferences	410
3. Supply-Side Drivers of Clinical Decisions	411
3.1. Profits versus Patients	412
3.2. Payment Systems and Supplier-induced Demand	413
3.3. Physician Specialization and Training	415
3.4. Defensive Medicine	418
4. Situational Factors	419
4.1. Availability Heuristic	420
4.2. Framing, Choice, and Risk	421
4.3. Status Quo and Confirmation Bias	422
4.4. Channel Factors	422
4.5. Resource/Capability Factors	423
5. Conclusion	425
References	425
<b>7. Theoretical Issues Relevant to the Economic Evaluation of Health Technologies</b>	<b>433</b>
<i>David O. Meltzer, Peter C. Smith</i>	
1. Introduction	434
1.1. The Rationale for Economic Evaluation of Health Technologies	434
1.2. Institutional Contexts for CEA	436
2. Standard Approaches to Methodological Issues in Cost-Effectiveness Analysis	437
2.1. Introduction	437
2.2. Overview of the CEA Framework	438
2.3. Scope of the Analysis (Perspective)	440
2.4. Measuring Effectiveness in CEA	442
2.5. The Measurement of Costs in CEA	445
2.6. Applying CEA	447
3. Theoretical Foundations of CEA	448
3.1. Individual Utility Maximization and Cost-Effectiveness	449

3.2. A Mathematical Programming Perspective	452
3.3. Heterogeneity	454
3.4. Divisibility	455
3.5. Uncertainty	457
3.6. Value of Information Analysis	458
4. Continuing Debates in CEA	459
4.1. Perspective	460
4.2. Equity (Distributional) Considerations	462
4.3. Joint Costs/Benefits	464
4.4. Time Horizon and Discounting	465
5. Concluding Comments	466
References	467
<b>8. Cost Effectiveness and Payment Policy</b>	<b>471</b>
Alan M. Garber, Mark J. Sculpher	
1. Introduction	472
2. Measuring the Value of Health Interventions and Health System Performance	472
2.1. The QALY in Cost-effectiveness Analysis	472
2.2. Cost Effectiveness versus Cost/Benefit Analysis	474
3. Use of Cost-effectiveness Analysis for Decision Making	476
3.1. CEA in Principle—Decision Rules	476
3.2. Cost Effectiveness in Practice	479
3.3. Application Under Conditions of Uncertainty	481
3.4. Generating Information for Economic Analyses and Policy	482
4. Application to Payment and Coverage Policy	484
4.1. Beyond the Cost-effectiveness Ratio	492
References	494
<b>9. Competition in Health Care Markets</b>	<b>499</b>
Martin Gaynor, Robert J. Town	
1. Introduction	501
1.1. Market Environment	501
2. Entry, Exit, and Technology Investments by Providers	511
2.1. Structural Estimates of the Dynamic Behavior of Providers	515
2.2. Reduced Form Studies of Dynamic Behavior of Providers	517
3. Hospital Market Structure, Competition, and Prices	524
3.1. A Model of Hospital Insurer Negotiation	524
3.2. Estimating the Impact of Hospital Market Power on Price	533
3.3. Recent Developments in Antitrust Enforcement and Competition Policy in Health Care	552

4. Hospital Competition and Quality	559
4.1. Hospital Choice of Quality	560
4.2. Administratively Set Prices	561
4.3. Market Determined Prices	566
4.4. Econometric Studies of Hospital Competition and Quality	568
4.5. Summary	596
5. Studies of Health Insurance Markets	597
5.1. Introduction	597
5.2. Empirical Studies	598
5.3. Summary	609
6. Studies of Physician Services Markets	610
6.1. Introduction	610
6.2. Empirical Studies of Physician Services Markets	611
6.3. Summary	619
7. Vertical Restraints and Monopsony	619
7.1. Vertical Restraints	619
7.2. Health Care Providers and Monopsony Power	624
8. Summary and Conclusions	626
References	627

## **10. Health Care Markets, Regulators, and Certifiers** **639**

David Dranove

1. Introduction	640
2. Health Care Market Failure	641
2.1. Non-competitive Markets	641
2.2. Health Insurance and Moral Hazard	642
2.3. Information Asymmetry: Consumers and Producers	643
2.4. Intrinsic Motivation and Altruism	643
2.5. Quality Assurance Mechanisms	644
3. Market Structure and Provider Performance	646
3.1. Theoretical Effects of Health Care Competition: The Structure, Conduct, and Performance Paradigm	646
3.2. Empirical Studies of the Effects of Competition on Costs and Prices	649
3.3. Studies of Competition and Quality	654
3.4. Competition and Antitrust	658
4. Regulating Prices	663
4.1. Optimal Price Regulation	663
4.2. Regulated Prices and Quality	664
4.3. Empirical Evidence on Regulated Prices	665
5. Third Party Information Disclosure	668

5.1. Defining and Reporting Quality	669
5.2. Do Health Care Organizations Fully Disclose Quality?	673
5.3. Does Disclosure Improve Consumer Choice?	674
5.4. Does Disclosure Improve Quality?	677
5.5. Matching	679
5.6. Pay for Performance	680
5.7. Conclusion	683
6. Concluding Remarks	684
References	685
<b>11. Health Care Spending Risk, Health Insurance, and Payment to Health Plans</b>	<b>691</b>
Friedrich Breyer, M. Kate Bundorf, Mark V. Pauly	
1. Variation in Health Care Spending Between Persons and Over Time	692
1.1. Cross-sectional Variation across Individuals	695
1.2. Persistence in Health Expenditures	700
1.3. Implications	701
2. Insurance Market Equilibrium with Risk Variation and Rating Variation: Market Equilibrium Benchmarks	702
2.1. Equilibrium with Single-period Insurance and with No Regulation and No Information Asymmetry: Underwriting and Risk Rating	703
2.2. Equilibrium with Information Asymmetry: The Benchmark Adverse Selection Model and its Relevance to Health Insurance	705
2.3. Variation in Lifetime Risk versus Single Year Risk: Implications for Insurance Design and Market Equilibria	708
3. Group Insurance	713
3.1. Group Insurance Model and Theory	713
3.2. Group Insurance and Current-period Risk	714
3.3. Group Insurance and Risk Variation Over Time	719
4. Public Policy Toward Risk Variation	720
4.1. Regulation for Efficiency in Markets with Risk Variation	722
4.2. Regulation for Equity in Insurance Markets with Risk Variation	723
4.3. Government Intervention in Practice	724
5. Empirical Evidence on Insurance Market Performance	743
5.1. Risk Variation and the Demand for Insurance	743
5.2. Empirical Evidence on the Functioning of Insurance Markets	744
5.3. Empirical Methods Used to Examine Risk Selection	745
5.4. Empirical Evidence on Risk Selection	749
6. Interactions Between Risk Variation and Other Topics in Health Economics	754
6.1. Risk Variation and Insurance Pricing to Consumers: Bonus-Malus Systems, Discounts for Good Health Practices	754



7. Conclusion	755
7.1. Risk Variation in a Model of Public Choice: Will the Healthy People Outvote the Sick?	755
7.2. Whither Risk Policy?	756
References	756
<b>12. Markets for Pharmaceutical Products</b>	<b>763</b>
<i>Fiona Scott Morton, Margaret Kyle</i>	
1. Introduction	764
2. Overview of Regulation	765
2.1. Safety and Efficacy	765
2.2. Pricing and Reimbursement	768
2.3. Restrictions on Marketing, Prescribing, and Dispensing	768
3. Basic Facts on Pharmaceutical Expenditures and Prices	769
4. Market Structure	772
4.1. Supply Side	772
4.2. Demand Side	786
5. Competition	792
5.1. Generic Entry	792
5.2. Biologic Drugs and Biosimilars	797
5.3. Parallel Trade	798
5.4. Strategic Responses by Originators	799
6. Pricing and Marketing	801
6.1. International Prices	801
6.2. US	810
7. Marketing of Pharmaceuticals in the United States	815
8. Conclusion	818
References	819
<b>13. Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products</b>	<b>825</b>
<i>Dana Goldman, Darius Lakdawalla</i>	
1. Introduction	826
2. Forms of Intellectual Property Protection	828
2.1. Legal Exclusivity	828
2.2. Regulatory Exclusivity	830
2.3. Corporate Secrecy	831
3. Market Exclusivity and the Incentives to Innovate	832
3.1. The Simple Theory of Innovation	833
3.2. Empirical Evidence on the Simple Theory	833
3.3. IP Design and Incentives to Innovate	841

3.4. Cost Effectiveness and Innovation	847
4. The Normative Theory of Market Exclusivity	848
4.1. The Simple Normative Theory of Market Exclusivity and Innovation	848
4.2. Critiques of the Simple Theory and Their Implications	851
4.3. Political Economic Analysis	853
4.4. Unique Considerations for Medical Devices	854
5. The Role of IP in Solving Production Externalities	856
5.1. Pharmaceutical Marketing	856
5.2. Network Externalities and the Development of Health Care IT	860
5.3. Personalized Medicine and the Development of Diagnostic Testing	861
6. Alternative Approaches to Stimulating Discovery	862
6.1. Rewards for Inventors	862
6.2. Subsidies for Inventors	863
6.3. Health Insurance and Two-part Pricing	864
6.4. Patent Menus	866
6.5. The Case For and Against Government Buyers	866
References	868

## **14. Medical Workforce 873**

**Sean Nicholson, Carol Propper**

1. Introduction	874
2. Perfectly Functioning Medical Labor Markets	875
2.1. Supply of Labor	875
2.2. The Demand for Labor	877
2.3. Equilibrium	878
3. Labor Supply Topics	879
3.1. Rationale for Government Intervention in Medical Labor Markets	879
3.2. Licensing, Certification, and Accreditation: Objectives and Implications	881
3.3. Subsidizing Medical Education	889
3.4. Rates of Return to Medical Training and Specialization	890
3.5. Economics of Professional and Specialty Associations	892
3.6. How Elastic is Medical Workforce Labor Supply?	895
3.7. Physician Specialty Choice	895
3.8. Physicians' Geographic Location Decisions	897
3.9. Nurses' Labor Supply	898
3.10. Physicians' Labor Supply	899
3.11. Shortages and Surpluses of Medical Labor: Cyclicity and Persistence	901
4. Labor Demand Topics	904
4.1. Factor Demand: Own- and Cross-price Elasticity Estimates	905
4.2. Reimbursement, Politics, and Government Regulation	907
4.3. The Organizational Form of Firms: Why Do Physicians Form Groups?	911
4.4. Human Resource Management in Health Care	916

4.5. Motivated Agents	918
5. Areas for Future Research	919
References	919
<b>15. Public and Private Sector Interface</b>	<b>927</b>
<i>Pedro Pita Barros, Luigi Siciliani</i>	
1. Introduction	928
1.1. What do the Data tell Us?	931
1.2. Plan of the Chapter	931
2. Theory	934
2.1. A Tale of Two Margins	934
2.2. Funding	939
2.3. Provision	959
3. Empirical Evidence	981
3.1. Funding	981
3.2. Provision	986
3.3. Directions for Future Empirical Work on Public–Private Interface	994
4. Conclusions	994
References	995
<b>16. Equity in Health and Health Care</b>	<b>1003</b>
<i>Marc Fleurbaey, Erik Schokkaert</i>	
1. Introduction	1004
2. An Example	1005
3. Socioeconomic Inequity and Racial Disparities in Health and Health Care	1009
3.1. Socioeconomic Inequalities in Health and Health Care: The Concentration Curve and Index	1009
3.2. Racial Disparities in Health Care	1019
4. A More General Approach? Equality of Opportunity in Health and Health Care	1026
4.1. Equality of Opportunity and Fairness in Health and Health Care	1027
4.2. Substantive Debate: Where to Draw the Line between “Legitimate” and “Illegitimate” Inequalities?	1050
4.3. Empirical Applications	1058
5. Why Care About Equity in Health? Health and Well-being	1066
5.1. Equity in Finance	1067
5.2. Health and Well-being	1070
6. Conclusion	1085
References	1086
<b>Index</b>	<b>1093</b>